Editor's note: "US Stock Gold Mining" Keep up with daily market trends, insight, and consolidate hot and outstanding stocks, providing multi-dimensional investment opportunities for Mooer and helping them grasp investment opportunities with one chart! Focus on: 1. Performance and stock prices take off! Global fast fashion giant $Gap Inc (GPS.US)$ soared nearly 29% after its performance, reaching a new high for the year. Gap announced its first fiscal 2023 first-quarter results, with net sales of $3.4 billion, exceeding analysts' expectations of $3.28 billion, and earnings per share of $0.41, with overall comparable sales growth of 3%, better than expected 0.91%. In addition, the gross profit margin for the quarter reached 41.2%, higher than analysts' forecast of 38.5%. Its subsidiary brand Old Navy's same-store sales grew by 3%, exceeding market expectations of 2.5%. Based on this, Gap raised its sales and operating profit outlook for the year. Baird has recently raised its target share price for Gap from $23 to $28, and Goldman Sachs has raised its target share price for Gap from $20 to $27. 2. US electric power stocks collectively agitated! The largest wind and solar power generator developer in the United States $NextEra Energy (NEE.US)$, the fourth largest power plant in the United States $Southern Company (SO.US)$, the power and natural gas company $CenterPoint Energy (CNP.US)$, and the electrical production and transmission company $Edison International (EIX.US)$ have all reached new highs for the year. On the news front, as AI technology often requires a lot of energy to develop and operate, utility stocks are becoming a new opportunity for investors. 3. Low-key AI beneficiaries! Data storage giantThis week's bullish stocks in Hong Kong and the US stock markets.This section closely follows market trends every week, reviews the weekly performance of the Hong Kong and US stock markets, and helps mooers sort out the hot sectors, strong individual stocks, and major news of the week, looking for investment themes with profit potential.
Hang Seng Index fell by 0.43% within the week, closing at 17369.09 points; during the same period, the Hang Seng Tech Index fell by 0.23%, closing at 3479.8 points; the H-share Index fell by 0.56% during the same period, closing at 6071.52 points.
Despite the market fluctuations, many sectors and individual stocks have risen against the trend. Looking at the top gainers, pharmaceuticals, gold, and some excellent stocks have performed well.
Major positive news! $AKESO (09926.HK)$ Dual-antibody new drug clinical trials met expectations and outperformed the global 'drug king', surging to a record high of 28% within the week.
On the evening of September 8th, innovative drug company Akeso Bio released detailed data of its dual-target therapy in a phase III clinical trial, defeating the global "drug king" Merck's K drug, with significantly better efficacy than K drug. In this clinical trial called HARMONi-2, Akeso Bio's globally pioneering PD-1/VEGF dual-target therapy Yvorsi mono therapy was directly compared head-to-head against K drug, targeting first-line treatment of locally advanced or metastatic non-small cell lung cancer with positive PD-L1 expression. K drug is Merck's star product.
JP Morgan released a research report stating that Akeso Bio's self-developed Yvorsi monoclonal antibody injection (AK112) achieved success in a global phase III trial as a monotherapy, and they have more confidence in gaining more market share in China. Considering the upward adjustment of AK112's sales forecast, the corresponding sales forecast for Akeso Bio is raised by over 40%. The bank raised its target price to HKD 68, reiterating Akeso Bio as the preferred choice in China's biotechnology sector with a "buy" rating.
Strong Q2 financial report, with three consecutive increases in stock price after performance. $NIO-SW (09866.HK)$Up more than 20% during the week, with ratings upgraded by multiple major banks.
NIO Inc.'s rise is mainly due to its strong performance in the second quarter. The report shows that the company's revenue reached 17.45 billion yuan, a year-on-year growth of 98.9%, and deliveries of 57,373 vehicles, a year-on-year growth of 143.9%, both reaching historic highs. This performance exceeded market expectations. In addition, NIO's gross margin remained stable, and its sales guidance for the third quarter exceeded expectations, with projected sales of 0.061-0.063 million vehicles.
BOCOM International believes that with improved sales and adjusted promotional strategies, NIO Inc.'s gross margin will further improve in the third quarter, setting a target price of HKD 59.88 and a "buy" rating. JPMorgan upgraded NIO ADR to overweight and set a target price of $8.
Multiple positive factors stacking up. $LAOPU GOLD (06181.HK)$ Stock price reaches a new high! The company has been included in the Hong Kong stock connect, with its net profit increasing nearly doubled in the first half of the year.
On September 10th, the list of stocks included in the Hong Kong stock connect was officially adjusted. Among them, Lao Pu Gold was included, which is expected to attract more investor attention and inflow of funds.
In addition, the recent performance release of the company showed that in the first half of this year, Lao Pu Gold achieved a revenue of 3.52 billion yuan (same unit), an increase of 148.34% compared to the same period last year; the company's net profit attributable to shareholders was 0.588 billion yuan, an increase of 198.75% compared to the same period last year. Xinda Securities believes that as a scarce high-end traditional gold brand, the company is expected to achieve significant performance growth faster than its peers in the next 3 years and enjoy a certain valuation premium.
On the other hand, the following stocks performed weakly this week:
Editor/new
